Charles Dadswell Sells 116 Shares of Illumina Inc. (ILMN) Stock
Illumina Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 116 shares of the company’s stock in a transaction dated Tuesday, October 4th. The shares were sold at an average price of $182.38, for a total transaction of $21,156.08. Following the sale, the senior vice president now owns 39,900 shares of the company’s stock, valued at $7,276,962. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Charles Dadswell also recently made the following trade(s):
- On Wednesday, July 27th, Charles Dadswell sold 8,632 shares of Illumina stock. The shares were sold at an average price of $155.00, for a total transaction of $1,337,960.00.
Illumina Inc. (NASDAQ:ILMN) opened at 184.93 on Friday. Illumina Inc. has a 52 week low of $127.10 and a 52 week high of $196.47. The company has a market capitalization of $27.11 billion, a PE ratio of 63.33 and a beta of 0.47. The firm has a 50-day moving average of $174.28 and a 200-day moving average of $156.11.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, July 26th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.13. The firm earned $600 million during the quarter, compared to the consensus estimate of $31.91 million. Illumina had a net margin of 18.73% and a return on equity of 23.69%. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.80 EPS. Equities analysts expect that Illumina Inc. will post $3.53 earnings per share for the current fiscal year.
A number of research analysts have recently commented on ILMN shares. Citigroup Inc. upped their price objective on shares of Illumina from $175.00 to $190.00 and gave the company a “buy” rating in a research report on Monday, September 12th. CL King lowered shares of Illumina from a “buy” rating to a “neutral” rating in a research report on Monday, August 22nd. Vetr raised shares of Illumina from a “sell” rating to a “buy” rating and set a $198.61 price objective for the company in a research report on Monday. Morgan Stanley lowered shares of Illumina from an “equal weight” rating to an “underweight” rating and cut their price objective for the company from $130.00 to $110.00 in a research report on Tuesday, July 5th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating on shares of Illumina in a research report on Wednesday, June 29th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and twelve have assigned a buy rating to the company’s stock. Illumina currently has an average rating of “Hold” and an average price target of $164.94.
A number of hedge funds have recently bought and sold shares of ILMN. Physicians Financial Services Inc. increased its stake in Illumina by 2,121.2% in the second quarter. Physicians Financial Services Inc. now owns 733 shares of the life sciences company’s stock worth $103,000 after buying an additional 700 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its stake in Illumina by 25.0% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 789 shares of the life sciences company’s stock worth $110,000 after buying an additional 158 shares in the last quarter. Fuller & Thaler Asset Management Inc. acquired a new stake in Illumina during the second quarter worth about $112,000. Ropes Wealth Advisors LLC increased its stake in Illumina by 72.6% in the second quarter. Ropes Wealth Advisors LLC now owns 863 shares of the life sciences company’s stock worth $121,000 after buying an additional 363 shares in the last quarter. Finally, Checchi Capital Advisers LLC increased its stake in Illumina by 2.4% in the second quarter. Checchi Capital Advisers LLC now owns 958 shares of the life sciences company’s stock worth $134,000 after buying an additional 22 shares in the last quarter. 95.22% of the stock is owned by hedge funds and other institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company’s products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies.
Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.